GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Aclarion Inc (NAS:ACON) » Definitions » LT-Debt-to-Total-Asset

Aclarion (Aclarion) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Aclarion LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Aclarion's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.

Aclarion's long-term debt to total assets ratio stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00).

Aclarion LT-Debt-to-Total-Asset Historical Data

The historical data trend for Aclarion's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclarion LT-Debt-to-Total-Asset Chart

Aclarion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
- - - - -

Aclarion Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aclarion LT-Debt-to-Total-Asset Calculation

Aclarion's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0/2.46
=0.00

Aclarion's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )/Total Assets (Q: Mar. 2024 )
=0/3.727
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aclarion  (NAS:ACON) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Aclarion LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Aclarion's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Aclarion (Aclarion) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Aclarion Inc (NAS:ACON) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
WORX KERN WLSS LGMK NHIQ FOXO INQR VYND HITC MITI GEHC VEEV TSE:2413 HQY ASX:PME RCM TXG DOCS PGNY TDOC
Traded in Other Exchanges
N/A
Address
8181 Arista Place, Suite 300, Broomfield, CO, USA, 80021
Website
http://www.aclarion.com
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
Executives
John Paul Lorbiecki officer: Chief Financial Officer 238 CHEYENNE DRIVE, LAFAYETTE CO 80026
Brent Ness director, officer: Chief Executive Officer 951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Ryan Bond officer: Chief Strategy Officer 951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Stephen Deitsch director 1600 BROADWAY, SUITE 700, DENVER CO 80202
William Wesemann director 130 MONTALVO ROAD, REDWOOD CITY CA 94062
Jeffrey John Thramann director, officer: Executive Chairman 8580 STRAWBERRY LANE, NIWOT CO 80503
Michael W Dirks 10 percent owner 811 EAST 30TH AVE, HUTCHINSON KS 67502
Nuvasive Inc 10 percent owner 7475 LUSK BLVD, SAN DIEGO CA 92121
Sc Capital 1 Llc 10 percent owner 1 COMPOUND DRIVE, HUTCHINSON KS 67502
Scott Breidbart director 951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404
Amanda Mae Sequira director 951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
David K Neal director C/O ACLARION, INC., 951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404